论文部分内容阅读
为探讨预处理方案对小儿自体外周血造血干细胞移植（Ａｕｔｏ－ＰＢＳＣＴ）疗效的影响，对１４例恶性肿瘤患儿（急性淋巴细胞白血病７例、急性髓系白血病４例、恶性淋巴瘤２例、神经母细胞瘤１例），在其完全缓解６个月后进行了Ａｕｔｏ－ＰＢＳＣＴ治疗。中位随访时间４．８年（３～７年）。结果无病生存率为５７％（８／１４），死亡率为４３％（６／１４）。初步资料结果表明，预处理方案采用全身照射（７．０±０．５Ｇｙ）联合３或４种化疗药物要比联合１～２或５种化疗药物为好，但在为每个患儿进行移植前制订预处理方案时，应注意个体化。
To investigate the effect of pretreatment on the curative effect of pediatric autologous peripheral blood hematopoietic stem cell transplantation (Auto-PBSCT), 14 patients with malignant tumor (acute lymphoblastic leukemia in 7, acute myeloid leukemia in 4, malignant lymphoma in 2, 1 neuroblastoma) and treated with Auto-PBSCT 6 months after complete remission. The median follow-up time was 4.8 years (3-7 years). Results The disease-free survival rate was 57% (8/14) and the mortality rate was 43% (6/14). Preliminary data showed that the pretreatment program with systemic irradiation (7.0 ± 0.5Gy) combined with 3 or 4 chemotherapy drugs than combined with 1 or 2 or 5 chemotherapy drugs is better, but for each child for transplantation Before formulating the pretreatment program, we should pay attention to individualization.